ALR Technologies Inc. (ALRTF) Stock Analysis
Educational signal · not a buy or sell recommendation · How to read this
Market cap $12.1M is the value of all shares combined. Beta 2.56: the stock has moved about 156% more than the S&P 500.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 16, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerALR Technologies Inc. (ALRTF) trades at $0.0188. ALR Technologies Inc. develops and markets diabetes care solutions for both human and animal health, including data management systems and continuous glucose monitoring. Market cap: $12.1M, Sector: Healthcare.
Price as of Sep 10, 2026 · Last analyzed: Mar 16, 2026Analyst Coverage for ALRTF: ALRTF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates ALRTF against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
No score published: this stock trades under $10,000 on a typical day, so the price beside it is not one you could reliably act on.
ALRTF: the 2 scored disciplines are evenly split. Dominant signal: Seth Klarman bullish.
How is this calculated? →AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
ALR Technologies Inc. (ALRTF) Healthcare & Pipeline Overview
ALR Technologies Inc. provides diabetes care solutions, including data management systems and continuous glucose monitoring (CGM) for humans and animals. Targeting healthcare providers and insurers, the company offers tools for data collection, predictive A1C, and remote monitoring, positioning itself in the evolving diabetes management market.
What Is the Investment Thesis for ALRTF?
ALR Technologies Inc. presents a focused play on the diabetes management market, targeting both human and animal health. The company's Diabetes Management System and CGM offerings address the growing need for comprehensive diabetes care solutions. A key value driver is the potential expansion of their GluCurve Pet CGM in the veterinary market, tapping into the increasing awareness and treatment of diabetes in pets. However, the company's negative P/E ratio of -1.35 and a significantly negative profit margin of -159306.4% raise concerns about its financial sustainability. Future growth hinges on successful market penetration and achieving profitability. Investors should closely monitor revenue growth, cost management, and the adoption rate of their pet-focused CGM solution.
Based on FMP financials and quantitative analysis
ALRTF Key Highlights
Market Cap of $12.1M indicates a micro-cap company with high growth potential but also higher risk.
- Gross Margin of 66.2% suggests a strong ability to control production costs relative to revenue.
- Negative P/E ratio of -1.35 reflects current unprofitability, requiring careful evaluation of future earnings potential.
- Profit Margin of -159306.4% indicates significant operational challenges and the need for improved cost management.
- Beta of 2.56 suggests high volatility compared to the market, indicating a riskier investment.
Who Are ALRTF's Competitors?
ALRTF is benchmarked below against 3 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| ANPCY CelLBxHealth plc | $0.07 | 0.00% | $22.0M | — |
| IMUC EOM Pharmaceuticals Holdings, Inc. | $0.15 | +0.66% | $19.2M | — |
| NUMIF Numinus Wellness Inc. | $0.03 | +8.11% | $8.98M | — |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are ALRTF's Key Strengths?
Comprehensive Diabetes Management System.
- Unique GluCurve Pet CGM product for animal health.
- Focus on data-driven insights and remote monitoring.
- Integrated system for both human and animal diabetes care.
What Are ALRTF's Weaknesses?
Negative profit margin and reliance on external funding.
- Limited market presence and brand recognition.
- Small number of employees and limited resources.
- Dependence on the success of a few key products.
What Could Drive ALRTF Stock Higher?
Potential partnerships with veterinary clinics to expand GluCurve Pet CGM sales.
- Development of new features and functionalities for the Diabetes Management System.
- Increasing awareness of diabetes in pets driving demand for GluCurve Pet CGM.
- Growing adoption of remote monitoring and data-driven diabetes management solutions.
What Are the Key Risks for ALRTF?
Competition from established players in the diabetes care market.
- Regulatory changes and healthcare reforms impacting product approvals and reimbursement.
- Technological advancements that could render their products obsolete.
- Limited financial resources and reliance on external funding.
- Negative profit margin and challenges in achieving profitability.
What Are the Growth Opportunities for ALRTF?
- Expansion of GluCurve Pet CGM: The market for pet diabetes care is growing, driven by increased pet ownership and awareness of pet health. ALR Technologies' GluCurve Pet CGM addresses a specific need in this market, offering veterinarians a tool for effective diabetes management in cats and dogs. Successful market penetration and partnerships with veterinary clinics could significantly boost revenue. The pet diabetes care market is projected to reach $1.5 billion by 2028.
- Adoption of Diabetes Management System: The Diabetes Management System offers a comprehensive solution for healthcare providers and insurers. Increased adoption of this system can drive revenue growth. The global diabetes management market is expected to reach $25 billion by 2027, driven by the rising prevalence of diabetes and the need for effective management tools. ALR Technologies can capitalize on this trend by demonstrating the system's effectiveness in improving patient outcomes and reducing healthcare costs.
- Partnerships with Healthcare Providers: Collaborating with healthcare providers and integrating their solutions into existing healthcare systems can expand ALR Technologies' reach. Strategic partnerships can provide access to a wider patient base and enhance the credibility of their products. The healthcare IT market is growing rapidly, with a focus on interoperability and data-driven solutions. ALR Technologies can leverage this trend by offering seamless integration with existing healthcare platforms.
- Development of Prediabetes System: The Prediabetes System, with its educational content and online community, can attract a significant user base. By providing valuable resources and support, ALR Technologies can help individuals manage their prediabetes and potentially prevent the onset of type 2 diabetes. The prediabetes market is largely untapped, presenting a significant opportunity for growth. Early intervention and lifestyle management programs are gaining traction, creating a demand for solutions like ALR Technologies' Prediabetes System.
- Geographic Expansion: While currently focused on the United States, ALR Technologies can explore opportunities to expand its market reach to other countries. The global diabetes market is vast, and international expansion can significantly increase revenue. Emerging markets with growing diabetes prevalence offer particularly attractive opportunities. However, navigating regulatory requirements and cultural differences in different countries will be crucial for successful expansion.
What Are ALRTF's Competitive Advantages?
- Specialized focus on both human and animal diabetes care.
- Proprietary Diabetes Management System with data-driven insights.
- GluCurve Pet CGM addresses a specific need in the veterinary market.
- Integrated system combining data collection, monitoring, and support.
What Does ALRTF Do?
ALR Technologies Inc., initially named Mo Betta Corp. before rebranding in 1998, was founded in 1987 and is headquartered in Richmond, Virginia, operating as a subsidiary of ALR Technologies SG Ltd. The company focuses on developing data-driven diabetes care solutions for both human and animal health markets. Their core product is the Diabetes Management System, a comprehensive platform that integrates data collection, predictive A1C calculations, insulin dosage suggestions, performance tracking, and remote monitoring. This system also includes diabetes test supplies. ALR Technologies also offers Continuous Glucose Monitoring (CGM) devices for real-time blood sugar readings in humans. Recognizing a gap in the animal health market, they developed GluCurve Pet CGM, specifically designed for feline and canine diabetes management, targeting veterinary professionals. Furthermore, ALR Technologies provides a Prediabetes System, featuring educational videos, mobile-friendly content, and an online community to support patients in managing prediabetes. The company's primary customer base includes healthcare providers, health insurance companies, and providers of disease and case management services, including the home care industry.
What Products and Services Does ALRTF Offer?
- Develops Diabetes Management System for data collection and analysis.
- Offers predictive A1C calculations and insulin dosage suggestions.
- Provides Continuous Glucose Monitoring (CGM) devices for human use.
- Manufactures GluCurve Pet CGM for diabetes management in cats and dogs.
- Creates Prediabetes System with educational videos and online community.
- Offers remote monitoring and performance tracking solutions for diabetes care.
- Provides diabetes test supplies as part of its comprehensive system.
How Does ALRTF Make Money?
- Sells Diabetes Management System to healthcare providers and insurers.
- Generates revenue from the sale of CGM devices and related supplies.
- Offers GluCurve Pet CGM to veterinarians for animal diabetes management.
- Provides Prediabetes System subscriptions and related content.
What Industry Does ALRTF Operate In?
ALR Technologies Inc. operates within the medical device industry, specifically targeting the diabetes care market. This market is driven by the increasing prevalence of diabetes globally, creating a demand for innovative monitoring and management solutions. The competitive landscape includes established players offering CGMs and diabetes management platforms. ALR Technologies differentiates itself by focusing on both human and animal health, with its GluCurve Pet CGM addressing a niche market. The industry is also influenced by technological advancements in remote monitoring and data analytics, which are integral to ALR Technologies' offerings.
Who Are ALRTF's Key Customers?
- Healthcare providers (doctors, clinics, hospitals)
- Health insurance companies
- Veterinarians and animal health clinics
- Individuals with diabetes or prediabetes
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● Price is current
- ● No filing on record
- ● No analyst coverage
Key Financial Metrics
Return on equity for ALR Technologies Inc. stands at 51.6%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 0.01 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -74.1%, the inverse of the P/E and a quick read on earnings relative to price.
ALRTF Valuation & Market Position
With a $12.1M market cap, ALR Technologies Inc. sits in the micro-cap segment of the market.
Company Profile
ALR Technologies Inc. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Singapore, SG. The company is led by CEO Sidney S. Chan. ALRTF has traded publicly since 1998.
ALRTF Financials
Bull Case vs Bear Case
Bull Case
- Comprehensive Diabetes Management System.
- Unique GluCurve Pet CGM product for animal health.
- Focus on data-driven insights and remote monitoring.
- Integrated system for both human and animal diabetes care.
Bear Case
- Negative profit margin and reliance on external funding.
- Limited market presence and brand recognition.
- Small number of employees and limited resources.
- Dependence on the success of a few key products.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
ALRTF Latest News
No recent news available for ALRTF.
ALRTF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for ALRTF.
Price Targets
Wall Street price target analysis for ALRTF.
ALRTF MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for ALRTF; grades run from A+ (80-100) to F (below 30).
Leadership: Sidney S. Chan
CEO
Sidney S. Chan is the CEO of ALR Technologies Inc. His background includes experience in managing and growing technology-focused companies. He is responsible for the overall strategic direction and operational execution of the company. He leads a small team of 7 employees, focusing on developing and marketing diabetes care solutions for both human and animal health. His expertise lies in identifying market opportunities and driving product innovation.
Track Record: Under Sidney Chan's leadership, ALR Technologies Inc. has focused on expanding its product offerings in the diabetes care market, including the development of the GluCurve Pet CGM. Key milestones include securing partnerships with veterinary clinics and expanding the reach of the Diabetes Management System. However, the company's financial performance remains a challenge, with ongoing efforts to improve profitability and secure additional funding.
ALRTF OTC Market Information
The OTC Other tier, where ALR Technologies Inc. trades, represents the lowest tier of the OTC market. Companies in this tier often have limited or no financial disclosure, and may not meet minimum listing requirements. This tier is distinct from exchanges like NYSE or NASDAQ, which have stringent listing standards, including minimum share price, market capitalization, and financial reporting requirements. Companies on OTC Other may be subject to less regulatory oversight, increasing investment risk.
- OTC Tier: OTC Other
- Limited financial disclosure increases the risk of investing in ALRTF.
- Lower liquidity can make it difficult to buy or sell shares at desired prices.
- The OTC Other tier is associated with higher risk of fraud and manipulation.
- Lack of regulatory oversight compared to listed exchanges.
- Potential for delisting or trading suspension due to non-compliance.
- Verify the company's registration and legal standing.
- Review available financial statements, if any, and assess their accuracy.
- Research the company's management team and their track record.
- Understand the company's business model and competitive landscape.
- Assess the liquidity of the stock and potential trading risks.
- Consult with a financial advisor before investing.
- Be aware of the risks associated with investing in OTC stocks.
- The company has been in operation since 1987.
- ALR Technologies Inc. has a specific focus on diabetes care solutions.
- The company has developed products for both human and animal health.
- The company operates as a subsidiary of ALR Technologies SG Ltd.
ALR Technologies Inc. Healthcare Stock: Key Questions Answered
Is ALRTF a good stock?
Stock Expert AI does not rate ALRTF buy, sell or hold. ALR Technologies Inc. has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns, what the price assumes, and what would prove you wrong.
What does ALR Technologies Inc. do?
ALR Technologies Inc. is a data management company that develops and markets diabetes care solutions for both human and animal health.
What do analysts say about ALRTF stock?
There is currently no available analyst coverage or consensus on ALRTF stock. Given its OTC listing and micro-cap status, the stock may not be widely followed by analysts. Investors should conduct their own thorough research and due diligence before investing. Key valuation metrics to consider include revenue growth, gross margin, and profitability.
How does ALR Technologies Inc. differentiate itself in the competitive diabetes care market?
ALR Technologies Inc. differentiates itself through its focus on both human and animal diabetes care, with the GluCurve Pet CGM addressing a specific need in the veterinary market.
What are the key factors to evaluate for ALRTF?
Evaluate ALRTF on fundamentals, analyst consensus, and risk factors. ALR Technologies Inc. presents a focused play on the diabetes management market, targeting both human and animal health. Not financial advice.
How frequently does ALRTF data refresh on this page?
ALRTF's price was last updated on Sep 10, 2026 and refreshes on page view during U.S. market hours; the quote is a provider snapshot, not an exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven ALRTF's recent stock price performance?
ALR Technologies Inc. (ALRTF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Comprehensive Diabetes Management System. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider ALRTF overvalued or undervalued right now?
ALR Technologies Inc. (ALRTF) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available for OTC-traded companies.
- Financial data based on available information and may not be comprehensive.
- Analyst consensus and price targets may not be available due to limited coverage.